655
Participants
Start Date
January 12, 2018
Primary Completion Date
June 30, 2018
Study Completion Date
July 3, 2018
Diclofenac Sodium Gel
Twice daily for 60 days. Each patient is expected to receive 120 doses
Solaraze 3% Topical Gel
Twice daily for 60 days. Each patient is expected to receive 120 doses
Placebo
Twice daily for 60 days. Each patient is expected to receive 120 doses
PEAK Research, LLC, Upper Saint Clair
DermDox Centers for Dermatology, Hazleton
Health Research of Hampton Roads, Inc., Newport News
Dermatology Consulting Services, High Point
Greenville Dermatology, LLC, Greenville
Anderson Dermatology, Anderson
Multi-Speciality Research Associates, Inc., Lake City
Ormond Medical Arts Pharmaceutical Research Center, Ormond Beach
Solutions Through Advanced Research, Inc., Jacksonville
FXM Research Miramar, Miramar
Universal Medical and Research Center, LLC, Coral Gables
FXM Research, Miami
Health Awareness, Inc., Jupiter
Moore Clinical Research, Tampa
Forward Clinical Trials, Tampa
DS Research, Louisville
Sterling Research Group, Cincinnati
DS Research, New Albany
Minnesota Clinical Study Center, Fridley
Dermatology Trial Associates, Bryant
Sirius Clinical Research, LLC, Austin
Northwest Clinical Trials, Boise
DTRL, Inc., Henderson
West Coast Research, San Ramon
Lead Sponsor
Collaborators (1)
Novum Pharmaceutical Research Services
INDUSTRY
Encube Ethicals Pvt. Ltd.
INDUSTRY